XML 30 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 9 - Intangible Assets
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]
9.
Intangible Assets
In connection with the 2009 acquisition of Anika Therapeutics S.r.l. (“Anika S.r.l.”), the Company acquired various intangible assets and goodwill. The Company evaluated the various intangible assets and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangible assets. The in-process research and development (“IPR&D”) intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition, including write-off(s) for abandoned projects. Until such determination is made, they are not amortized. 
 
Intangible assets as of March 31, 2016 and December 31, 2015 consist of the following:
 
        March 31, 2016   December 31, 2015
    Gross Value   Accumulated Currency Translation Adjustment   Accumulated Amortization   Net Book Value   Net Book Value   Useful Life
Developed technology   $ 17,100     $ (2,882 )   $ (6,148 )   $ 8,070     $ 7,959       15  
In-process research & development     4,406       (1,193 )     -       3,213       3,099       Indefinite  
Distributor relationships     4,700       (415 )     (4,285 )     -       -       5  
Patents     1,000       (173 )     (345 )     482       473       16  
Elevess trade name     1,000       -       (906 )     94       125       9  
Total   $ 28,206     $ (4,663 )   $ (11,684 )   $ 11,859     $ 11,656          
 
The aggregate amortization expense related to intangible assets was $0.3 million for the three-month periods ended March 31, 2016 and 2015, respectively.